Structure-based drug repositioning explains ibrutinib as VEGFR2 inhibitor-Reference-Cited by-同舟云学术

Structure-based drug repositioning explains ibrutinib as VEGFR2 inhibitor

Published:2020-05-27 Issue:5 Volume:15 Page:e0233089
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Adasme Melissa F.^ORCID,Parisi Daniele,Van Belle Kristien,Salentin Sebastian,Haupt V. Joachim^ORCID,Jennings Gary S.,Heinrich Jörg-Christian,Herman Jean,Sprangers Ben,Louat Thierry^ORCID,Moreau Yves,Schroeder Michael

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference43 articles.

1. Ten thousand interactions for the molecular biologist;Patrick Aloy;Nature biotechnology,2004

2. Structural space of protein–protein interfaces is degenerate, close to complete, and highly connected;Mu Gao;Proceedings of the National Academy of Sciences,2010

3. Drug promiscuity in pdb: protein binding site similarity is key;V Joachim Haupt;PLoS one,2013

4. Network pharmacology: the next paradigm in drug discovery;Andrew L Hopkins;Nature chemical biology,2008

5. Data completeness—the achilles heel of drug-target networks;Jordi Mestres;Nature biotechnology,2008

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development of newer generation Vascular endothelial growth factor Receptor-2 Inhibitors: Pharmacophore based design, virtual Screening, molecular Docking, molecular dynamic Simulation, and DFT analyses;Journal of King Saud University - Science;2024-09

2. Clinical Research Progress of BTK Inhibitors in the Treatment of Autoimmune Diseases;Current Topics in Medicinal Chemistry;2023-11

3. Machine Learning Modeling Predicting Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) Inhibitors Structure-Activity Relationships Using Quantum DFT Descriptors;2023 XLIX Latin American Computer Conference (CLEI);2023-10-16

4. AI-Powered Virtual Screening of Large Compound Libraries Leads to the Discovery of Novel Inhibitors of Sirtuin-1;Journal of Medicinal Chemistry;2023-07-27

5. Repurposing of neprilysin inhibitor ‘sacubitrilat’ as an anti-cancer drug by modulating epigenetic and apoptotic regulators;Scientific Reports;2023-06-19